Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.
Palmieri G, Montella L, Milo M, Fiore R, Biondi E, Bianco AR, Martignetti A. Palmieri G, et al. Among authors: milo m. Am J Clin Oncol. 2002 Jun;25(3):224-6. doi: 10.1097/00000421-200206000-00003. Am J Clin Oncol. 2002. PMID: 12040276 Clinical Trial.
"It has to be better, otherwise we will get stuck." A Review of Novel Directions for Mental Health Reform and Introducing Pilot Work in the Netherlands.
van Os J, Scheepers F, Milo M, Ockeloen G, Guloksuz S, Delespaul P. van Os J, et al. Among authors: milo m. Clin Pract Epidemiol Ment Health. 2023 Nov 17;19:e17450179271206. doi: 10.2174/0117450179271206231114064736. eCollection 2023. Clin Pract Epidemiol Ment Health. 2023. PMID: 38680529 Free PMC article. Review.
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.
Bashi AC, Coker EA, Bulusu KC, Jaaks P, Crafter C, Lightfoot H, Milo M, McCarten K, Jenkins DF, van der Meer D, Lynch JT, Barthorpe S, Andersen CL, Barry ST, Beck A, Cidado J, Gordon JA, Hall C, Hall J, Mali I, Mironenko T, Mongeon K, Morris J, Richardson L, Smith PD, Tavana O, Tolley C, Thomas F, Willis BS, Yang W, O'Connor MJ, McDermott U, Critchlow SE, Drew L, Fawell SE, Mettetal JT, Garnett MJ. Bashi AC, et al. Among authors: milo m. Cancer Discov. 2024 May 1;14(5):846-865. doi: 10.1158/2159-8290.CD-23-0388. Cancer Discov. 2024. PMID: 38456804 Free PMC article.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembé AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST. Hardaker EL, et al. Among authors: milo m. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4. Nat Commun. 2024. PMID: 38402224 Free PMC article.
An open source auto-segmentation algorithm for delineating heart and substructures - Development and validation within a multicenter lung cancer cohort.
Olloni A, Lorenzen EL, Jeppesen SS, Diederichsen A, Finnegan R, Hoffmann L, Kristiansen C, Knap M, Milo MLH, Møller DS, Pøhl M, Persson G, Sand HMB, Sarup N, Thing RS, Brink C, Schytte T. Olloni A, et al. Among authors: milo mlh. Radiother Oncol. 2024 Feb;191:110065. doi: 10.1016/j.radonc.2023.110065. Epub 2023 Dec 19. Radiother Oncol. 2024. PMID: 38122851 Free article.
Response to "Letter to the Editor of Radiotherapy and Oncology regarding the paper titled Radiation dose to heart and cardiac substructures and risk of coronary artery disease in early breast cancer patients: A DBCG study based on modern radiation therapy techniques".
Milo MLH, Offersen BV. Milo MLH, et al. Radiother Oncol. 2023 Sep;186:109733. doi: 10.1016/j.radonc.2023.109733. Epub 2023 Jun 14. Radiother Oncol. 2023. PMID: 37327974 No abstract available.
Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
Di Dalmazi G, Coluzzi S, Baldassarre MPA, Ghit A, Graziano G, Rossi MC, Ciappini B, Milo M, Carrieri F, Nicolucci A, Consoli A, Formoso G. Di Dalmazi G, et al. Among authors: milo m. Front Endocrinol (Lausanne). 2022 Jul 15;13:892702. doi: 10.3389/fendo.2022.892702. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35909534 Free PMC article.
81 results